Opiant Pharmaceuticals Inc (NASDAQ:OPNT) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy rating.
Analysts have set a 12 month consensus price target of $41.33 for the company and are predicting that the company will post ($0.47) EPS for the current quarter, according to Zacks. Zacks has also assigned Opiant Pharmaceuticals an industry rank of 78 out of 256 based on the ratings given to its competitors.
A number of equities research analysts have commented on the stock. ValuEngine cut shares of Universal Electronics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 6th. Northland Securities assumed coverage on shares of Opiant Pharmaceuticals in a research note on Wednesday, May 29th. They set an “outperform” rating and a $42.00 target price on the stock.
Several hedge funds have recently bought and sold shares of OPNT. Advisor Group Inc. grew its holdings in shares of Opiant Pharmaceuticals by 57.2% in the fourth quarter. Advisor Group Inc. now owns 4,700 shares of the technology company’s stock valued at $69,000 after purchasing an additional 1,710 shares in the last quarter. BlackRock Inc. grew its holdings in shares of Opiant Pharmaceuticals by 44.0% in the fourth quarter. BlackRock Inc. now owns 10,259 shares of the technology company’s stock valued at $149,000 after purchasing an additional 3,137 shares in the last quarter. Spark Investment Management LLC grew its holdings in shares of Opiant Pharmaceuticals by 17.6% in the first quarter. Spark Investment Management LLC now owns 15,100 shares of the technology company’s stock valued at $198,000 after purchasing an additional 2,265 shares in the last quarter. Granite Investment Partners LLC purchased a new position in shares of Opiant Pharmaceuticals in the first quarter valued at $356,000. Finally, Northern Trust Corp grew its holdings in shares of Opiant Pharmaceuticals by 3.5% in the fourth quarter. Northern Trust Corp now owns 41,803 shares of the technology company’s stock valued at $604,000 after purchasing an additional 1,398 shares in the last quarter. 20.06% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ:OPNT traded down $0.56 during trading on Friday, hitting $13.05. The company’s stock had a trading volume of 15,233 shares, compared to its average volume of 16,513. The company has a 50-day simple moving average of $12.74. Opiant Pharmaceuticals has a 12 month low of $9.98 and a 12 month high of $29.55. The firm has a market cap of $51.29 million, a price-to-earnings ratio of -1.84 and a beta of 0.44.
Opiant Pharmaceuticals (NASDAQ:OPNT) last issued its quarterly earnings data on Thursday, May 9th. The technology company reported ($0.44) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.88) by $0.44. Opiant Pharmaceuticals had a negative net margin of 30.98% and a negative return on equity of 32.67%. The firm had revenue of $5.44 million for the quarter, compared to analysts’ expectations of $1.90 million. On average, analysts forecast that Opiant Pharmaceuticals will post 0.4 earnings per share for the current fiscal year.
About Opiant Pharmaceuticals
Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.
Featured Story: What is a short straddle?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.